BioCryst [BCRX] vs Zoetis [ZTS] Detailed Stock Comparison

BioCryst Pharmaceuticals Inc.

NASDAQ
Loading...

Zoetis Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: BioCryst Pharmaceuticals Inc. wins in 11 metrics, Zoetis Inc. wins in 9 metrics, with 0 ties. BioCryst Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric BioCryst Pharmaceuticals Inc. Zoetis Inc. Better
P/E Ratio (TTM) 7.09 19.58 BioCryst Pharmaceuticals Inc.
Price-to-Book Ratio -15.53 15.04 Zoetis Inc.
Debt-to-Equity Ratio -4.01 279.59 Zoetis Inc.
PEG Ratio -0.01 2.81 Zoetis Inc.
EV/EBITDA 6.71 13.96 BioCryst Pharmaceuticals Inc.
Profit Margin (TTM) 30.16% 28.24% BioCryst Pharmaceuticals Inc.
Operating Margin (TTM) 65.60% 34.69% BioCryst Pharmaceuticals Inc.
EBITDA Margin (TTM) 65.60% 34.69% BioCryst Pharmaceuticals Inc.
Return on Equity -221.45% 65.99% Zoetis Inc.
Return on Assets (TTM) 43.22% 15.26% BioCryst Pharmaceuticals Inc.
Free Cash Flow (TTM) $344.90M $2.28B Zoetis Inc.
Dividend Yield N/A 1.21% N/A
1-Year Return -16.10% -51.58% BioCryst Pharmaceuticals Inc.
Price-to-Sales Ratio (TTM) 2.46 5.26 BioCryst Pharmaceuticals Inc.
Enterprise Value $2.35B $56.75B Zoetis Inc.
EV/Revenue Ratio 2.69 6.00 BioCryst Pharmaceuticals Inc.
Gross Profit Margin (TTM) 97.66% 70.17% BioCryst Pharmaceuticals Inc.
Revenue per Share (TTM) $4 $21 Zoetis Inc.
Earnings per Share (Diluted) $1.21 $6.02 Zoetis Inc.
Beta (Stock Volatility) 0.69 0.97 BioCryst Pharmaceuticals Inc.
Short % of Float 14.08% 4.06% Zoetis Inc.

BioCryst Pharmaceuticals Inc. vs Zoetis Inc. Stock Performance Analysis

Loading Price Chart...

BCRX
ZTS

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
BioCryst Pharmaceuticals Inc.4.14%7.47%0.44%-2.58%19.37%20.80%
Zoetis Inc.1.51%0.16%3.42%-31.08%-32.94%-36.81%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
BioCryst Pharmaceuticals Inc.-16.10%17.41%-45.25%210.71%117.50%-30.40%
Zoetis Inc.-51.58%-53.40%-57.08%71.34%156.59%156.59%

Performance & Financial Health Analysis: BioCryst Pharmaceuticals Inc. vs Zoetis Inc.

MetricBCRXZTS
Market Information
Market Cap i$2.20B$49.75B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i4,555,2972,727,710
90 Day Avg. Volume i6,070,5623,835,940
Last Close$9.06$167.10
52 Week Range$6.00 - $10.47$139.70 - $200.33
% from 52W High-13.47%-16.59%
All-Time High$37.25 (Mar 06, 2000)$249.27 (Dec 27, 2021)
% from All-Time High-75.68%-32.96%
Growth Metrics
Quarterly Revenue Growth2.09%0.03%
Quarterly Earnings Growth2.09%0.04%
Financial Health
Profit Margin (TTM) i0.30%0.28%
Operating Margin (TTM) i0.66%0.35%
Return on Equity (TTM) i-2.21%0.66%
Debt to Equity (MRQ) i-4.01279.59
Cash & Liquidity
Book Value per Share (MRQ)$-0.56$7.84
Cash per Share (MRQ)$1.10$5.48
Operating Cash Flow (TTM) i$347.37M$2.90B
Levered Free Cash Flow (TTM) i$256.42M$1.79B
Dividends
Last 12-Month Dividend Yield iN/A1.21%
Last 12-Month Dividend iN/A$2.03

Valuation & Enterprise Metrics Analysis: BioCryst Pharmaceuticals Inc. vs Zoetis Inc.

MetricBCRX (Apr 24, 2026)ZTS (Apr 13, 2026)
Price Ratios
P/E Ratio (TTM) i7.0919.58
Forward P/E i10.7015.61
PEG Ratio i-0.012.81
Price to Sales (TTM) i2.465.26
Price to Book (MRQ) i-15.5315.04
Market Capitalization
Market Capitalization i$2.20B$49.75B
Enterprise Value i$2.35B$56.75B
Enterprise Value Metrics
Enterprise to Revenue i2.696.00
Enterprise to EBITDA i6.7113.96
Risk & Other Metrics
Beta i0.690.97
Book Value per Share (MRQ) i$-0.56$7.84

Financial Statements Comparison: BioCryst Pharmaceuticals Inc. vs Zoetis Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBCRX (2025)ZTS (2025)
Revenue/Sales i874.84M9.47B
Cost of Goods Sold i19.08M2.67B
COGS % of Revenue i2.2%28.2%
Gross Profit i855.76M6.80B
Gross Margin i97.8%71.8%
Research & Development i166.13M698.00M
Operating Income (EBIT) i340.99M3.60B
Operating Margin i39.0%38.0%
EBITDA i365.14M4.17B
EBITDA Margin i41.7%44.1%
Pre-Tax Income i267.39M3.36B
Pre-Tax Income % of Revenue i30.6%35.5%
Income Tax i3.53M687.00M
Income Tax % of Revenue i0.4%7.3%
Net Income (Profit) i263.86M2.67B
Profit Margin i30.2%28.2%

Balance Sheet & Liquidity Metrics

MetricBCRX (2025)ZTS (2025)
Cash & Equivalents i89.74M2.31B
Total Current Assets i404.35M6.77B
Total Current Assets % of Revenue i46.2%71.5%
Total Current Liabilities i196.07M2.24B
Total Current Liabilities % of Revenue i22.4%23.6%
Long-Term Debt i437.25M9.24B
Long-Term Debt % of Revenue i50.0%97.6%
Total Shareholders Equity i-119.15M3.33B
Retained Earnings i-1.51B13.74B
Retained Earnings % of Revenue i-172.2%145.2%
Property, Plant & Equipment i15.80M288.00M

Cash Flow Statement Comparison

MetricBCRX (2025)ZTS (2025)
Operating Cash Flow i327.78M2.78B
Operating Cash Flow % of Revenue i37.5%29.3%
Capital Expenditures i-2.47MN/A
Free Cash Flow i344.90M2.28B
FCF Margin i39.4%24.1%
Debt Repayment i-301.99M-1.35B
Common Stock Repurchase iN/A-3.24B

Short Interest & Institutional Ownership Analysis

MetricBCRXZTS
Shares Short i35.19M15.12M
Short Ratio i5.353.60
Short % of Float i14.08%4.06%
Shares Outstanding i213.06M424.93M
Float Shares i218.18M421.29M
% Held by Insiders i1.31%0.15%
% Held by Institutions i89.14%101.50%
% Held by Public i9.55%-1.65%

Dividend Analysis & Yield Comparison: BioCryst Pharmaceuticals Inc. vs Zoetis Inc.

MetricBCRXZTS
Last 12-Month Dividend iN/A$2.03
Last 12-Month Dividend Yield iN/A1.21%
3-Year Avg Annual Dividend iN/A$1.80
3-Year Avg Dividend Yield iN/A0.29%
3-Year Total Dividends iN/A$5.39
Ex-Dividend DateN/AJan 20, 2026